NCT07220408View on ClinicalTrials.gov

Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Allergic Conjunctivitis
Interventions
DRUG

TL-925

TL-925 is an eye drop.

DRUG

Placebo

The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.

Trial Locations (1)

37167

Advancing Vision Research, Smyrna

All Listed Sponsors
lead

Telios Pharma, Inc.

INDUSTRY